Since the eNOS directly mediates both contractility and permeability in collecting lymphatic vessels impaired in metabolic disease, restoring lymphatic eNOS activity while inhibiting the aberrant NO production by activated immune cells (Torrisi et al., 2016) (Rehal et al., 2020) is an attractive pharmacological target in metabolic disease. This evidence concerns the gene NOS3 and Other metabolic disease.